Akebia Therapeutics Inc. (NASDAQ:AKBA)
Bands
Volume
200 SMA
50 SMA
20 SMA
Videos
Alerts
Articles
Events
Old Forum Content for AKBA
Make a Forum Post Become a member to view recent forum posts. Already a member? Sign in here.
- Reif99: $AKBA trying to break out of a squeeze. Volatile, need a loose stop, but big potential. np
- AlexJFraser: $AKBA $NEO breaking out of squeeze
- AlexJFraser: $AKBA breaking out of weekly base...I think? @brobert maybe you can shed some light on this one?
- AlexJFraser: $AKBA is starting to look interesting. Took a small starter.
- AlexJFraser: @AlexJFraser $AKBA the daily chart right now looks a lot like $Vapo chart from May to June before it started moving up
- issues: Two of the best IBD industry groups in the medical field are 1) Biotech - group 4 - which includes: $NVAX $ADAP $CAPR $AKBA $APLT & $GMAB. The best are $NVAX $ADAP $AKBA & $CAPR The other IBD group is Medical products, group 13; $VIVO $LVGO $CODX $QDEL & $BSGM. We sold QDEL & AKBA at the high. We still hold $APLT $GMAB & $LVGO.
- Herb: @issues $NVAX $ADAP $CAPR $AKBA $APLT $GMAB $VIVO $LVGO $CODX $QDEL $BSGM $ADPT whackage AH
- spmeyers: $AKBA this biotech had strong buying end of day Friday; at trendline support, watching for move higher
- issues: I still like Biotech, even though it's dropped to IBD industry group 5 (from 2) I like these and own some of them: $BTAI $ADRO $CGEN $APTO $AKBA & $ADVM
- issues: Bought small positions in these biotechs: $BDSI $JNCE (flag/phase 2 pattern) $PFNX $AKBA $HZNP $NK $APTO $AMRN. Also added to $DTIL.
- issues: Looking at biotechs, I like these and are considering buying them: $JNCE $PFNX $MIRM $AKBA $HZNP $APTO $NK. We have many others but these are candidates RHRN. And you?
- bsafriet: @issues $JNCE $PFNX $MIRM $AKBA $HZNP $APTO $NK Txs for the watchlist. I’ve sold or got stopped out on what I was holding except for $ARWR - still have a BuCS on it, and $CYRX. Best wishes!
- issues: @bsafriet $JNCE $PFNX $MIRM $AKBA $HZNP $APTO $NK $ARWR $CYRX The way to hold is buy small and add. Just like ol' Danny advocates. I am listing biotech's only. CYRX is a transportation stock! CYRX is rated 46 D- (cumulative and accumulation) Not one I could imagine owning. The bio†echs I listed are all in IBD industry group #1 (out of 200 groups!) This has been the most profitable group to be in. Most are going up (not even sideways...)
- stairm01: @debeers $HZNP $PFNX Wondering if you have an opinion on $AKBA? Had a pop after earnings on high volume multiple days at the end of November and has consolidated and bounced off of $6.56 three times. Braking out above that level today on less than average volume since November 8, but higher than normal prior to that date. Looks as if buying is coming into this stock.
- issues: @Herb $MIRM Thank you for this addition to my list of the best biotechs: $AUPH $DCPH $ISEE $JNCE $HZNP $AMRN $PFNX $AKBA... we hold AUPH ISEE and others not listed.
- 1winkie: Akebia Therapeutics ($AKBA) surged on trial results
- woodman: $AKBA
- woodman: $AKBA - I set an alert for a cross above the 50 day.
- woodman: $AKBA - reviving after more than 3 weeks of pulling back following a nice pop. Now crossing above the 8dEMA. I have set an alert for a cross above the 50d which is not far above the 8d.
- tjv821: $akba playing wack a mole today
- tjv821: $akba still dropping
- tjv821: $akba so much for chasing
- debeers: @DrScience $akba --You are such a smarty pants. No really--you are! Do you know anyone who is doing what they are in kidney disease? Thanks, doctor.
- champ: $AKBA nice bounce in the AH's over 12%.....on News
- tjv821: $akba huge jump
- tjv821: $akba take the money and run??
- DrScience: @tjv821 $akba Factor in this tidbit: https://www.thestreet.com/story/14104429/1/akebia-surges-but-is-still-undervalued-making-takeover-a-potential-remedy.html. Still, taking a little profit here would be prudent.
- tjv821: @DrScience $akba thank you for the Intel I appreciate it
- tjv821: $akba ouch :(
- tjv821: $akba getting crushed
- tri2insite: @tjv821 $akba If you want to see crushed just look at $ENDP
- tjv821: $akba anyone else in this??
- tjv821: $akba anyone know why this is getting crushed??
- tjv821: $akba anyone else liking this??
- tjv821: $AKBA anyone else in this?
- champ: $AKBA - Climbing - $10.00 - Coming out of a squeeze and a 2 1/2 month consolidation. Has moved up from the 50, 100 and now the 8 day...in the last 7 days and now sitting on the upper boll band. Something going on...no real volume. I have been in this position for over a week now.
- Bridget: @champ not a bad looking chart. stick with it $AKBA
- judysteiner: $AKBA -IN THAT AS WELL AND BULLISH on AMERICA--GO!!
- judysteiner: $AKBA--JPM raises price to 24$
- champ: $AKBA -$9.00 - Watching this morning.... initiated with Outperform at JMP Securities with a target of $24. Public Offering was priced at $8.25. More and more buys keep coming out on this stock. $BLUE - $173 - on the move today. I'm day trading both and will swing all or part.
- champ: $AKBA $9.30 - HOD could move higher ...I'm still long this day trade for now.
- geothrills1: @champ $AKBA - The big squeeze just under the 50 DMA and the high volume breakout today is encouraging. I picked up some common at $9.27 and am asking $1 to sell July $10 calls against it. With the way the stock has been trading today (the July $10's hitting a high of $0.94 so far), I think getting a fill on the covered call position is a reasonable proposition, which would thereby reduce my cost basis to $8.27 per share and net a 21% gain in 30 days if the stock is above $10 at July expiration. If it's not above $10, the $8.27 basis is right at the breakout level of the recent two month base.
- champ: $AKBA - $9.95..HOD up $24% - Breaking out now. I already added and I will be swinging this day trade now. Going to try and have patients and let everybody take a look at this stock. More upgrades should be coming out in the coming days and weeks. The bottom has been made in this stock now IMO. IPO was March of 2014. I remember that $MS was really pushing this stock on the IPO and they had a very high price target. When I have time I will see if I can find it.
- lecoqsportif61: $akba anybody any thoughts about $akba?
- motomoto: $AKBA steady move higher this week into the consolidation zone. UBS and MS initiate coverage with targets in mid $20's. Adding here looking for break above $12.50
- Tricia: #BIOTECH EArnings week - 44 This Week! EArnings Mon 08/11 incl: $MACK $INO $AKBA $BLUE $RYLP $ENTA $PBYI $HALO (26 Today) Earnings Tues 08/12 incl: $INSY $BCRX $ARRY $RNA $PETX $STEM $ARWR (13) Earnings Wed 08/13 incl: $EPZM $CNAT $ONTX $TKMR There is a lot of data this week also .. should be very interesting $EPZM data at ASH Lymphoma meeting on August 12 $OPK will have top-line Rayaldee data on Monday night as well. Hep B Updates from $ARWR, $TKMR -- $ALNY will have another roundtable with $MDCO
- Tricia: $AKBA - so tough to hamg on to but so worht it .. chronic kidney disease play - great product and now BLUE SKY!
- grcjr: @Tricia $AKBA moving nicely today. Currently above the upper BB on a $2 move. Thanks for pointing this one out to us.
- bullmoose: $AKBA - Nice move over the past several days. Too late to buy now, but buy on the next pullback.
- Tricia: $AKBA: @grcjr - $25.74 pps up 16% - as we disussed Monday,I agressively bought back shares on the MS upgrade & PT of $90 and after AKBA announced the enrollment completion of its PII study - which the co believes wll have results by eo4thQ ... (very fast as this is an unmet need novel, efficaious and well tolerated treatment for anemia in CKD chronic kidney disease .... Up 16% today after 2 green days says -- hold if you have it and wait for a pb if you don't .... Or as Dan often advises buy 10 shares and watch & wait ...volatility is still here -
- grcjr: $AKBA @Tricia just covered on CNBC. Morgan Stanley upped price target huge on this highly spec play.
- grcjr: $AKBA $90 price target by Morgan Stanley. See http://www.wkrb13.com/markets/291170/akebia-therapeutics-stock-rating-reaffirmed-by-morgan-stanley-akba/
| Stock Price | $1.39 |
| Change | 0.00% |
| Volume | 2,546,510 |
Akebia Therapeutics Inc is a biopharmaceutical company. It is engaged in the development of proprietary therapeutics based on hypoxia inducible factor, or HIF, biology and the commercialization of these products for patients with kidney disease.
Request Video of AKBAAlready a member? Sign in here.
Past Month
Leading Peers
-
$5.07 259.09%
-
$5.46 129.20%
-
$5.11 79.40%
Past Month
Lagging Peers
-
$15.66 -104.82%
-
$30.02 -79.38%
-
$6.66 -69.76%
Dan Fitzpatrick
Stock Market Mentor gives you EVERYTHING you need to succeed in the market; all in one place. How easy is that? Dan Fitzpatrick and his elite community of traders share trading ideas, strategies and much more. Dan Fitzpatrick--a world class Technical Analyst, trading coach and regular CNBC contributor--gives you access to all of this with a 30 day trial membership for just $7.77. Get started TODAY and start trading better TOMORROW with the following premium content:
- Nightly video Strategy Sessions with a game plan for tomorrow
- Got a stock you want Dan to look at? Just ask.
- Patent pending video alerts instantly delivered to you when one of Dan’s trading signals is triggered. This is not your typical price alert. This is a short video explaining the action you need to take to make money. No more “Woulda, coulda, shoulda”
- Access to over 90,400 stock analysis videos
- Access an ever expanding library (90,400) of educational videos that will save you time and make you money
Join a team of friends and traders that have one thing in common; a burning desire to succeed.
Become a Member Today!
Gain immediate access to all our exclusive articles, features, how-to's, discussion group and much more...
Satisfaction Guaranteed!
Your Stock Market Mentor membership comes with a 30 day, no questions asked, 100% money back guarantee!